Business Wire

MA-CYBERARK

22.7.2022 17:30:09 CEST | Business Wire | Press release

Share
CyberArk Named a Leader in 2022 Gartner Magic Quadrant for Privileged Access Management

CyberArk (NASDAQ: CYBR ), the global leader in Identity Security , today announced it was named a Leader in the 2022 Gartner® Magic Quadrant™ for Privileged Access Management 1 . The company was positioned both highest in ability to execute and furthest in completeness of vision for the fourth time in a row.

According to the report, “While core PAM [privileged access management] products continue to be important security tools, shifting demand in the market has brought new emphasis on the cloud, from SaaS delivery of PAM tools, to expanding the functionality for cloud security in PAM tools, including secrets management and CIEM [cloud infrastructure entitlement management].”

Built for the dynamic enterprise, the CyberArk Identity Security Platform enables secure access for any identity from anywhere and to the widest range of resources or environments. Centered on intelligent privilege controls, the Platform addresses the broadest range of Identity Security requirements, all from a single admin portal with unified audit and continuous threat detection and response.

Helping customers enable Zero Trust by enforcing least privilege, CyberArk continues to innovate across its self-hosted solutions and expanding SaaS portfolio of privileged access management , endpoint privilege security, secrets management and cloud privilege security offerings. Last week, CyberArk announced new Identity Security offerings that address customer needs to secure an expanding range of identities that require privileged access, privileged elevation and access to a wide array of secrets. The announcements include CyberArk Secrets Hub , CyberArk Secure Cloud Access and Identity Security Intelligence , one of the Platform’s foundational shared services.

“Privileged access management must be at the core of Identity Security strategies in order for organizations to effectively drive down cybersecurity debt and securely and efficiently advance their digital business initiatives,” said Barak Feldman, senior vice president, CyberArk. “We’ve built a tremendous foundation of trust with over 7,500 global enterprise customers that rely on CyberArk as a long-term partner. The world’s leading organizations leverage our expanded privileged access management solutions as part of our Identity Security Platform to protect a growing number of human and machine identities across hybrid and multi-cloud environments. We are proud of our ability to consistently provide customers and partners with the support, training and flexible purchase and implementation models they require to be successful, and more secure.”

Additionally, CyberArk recently unveiled Privileged Access Manager Self-Hosted version 12.6 with credential management, session management and threat analytics enhancements and CyberArk Endpoint Privilege Manager for Linux .

To download a complimentary copy of the 2022 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2022-mq-pam

1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Michael Kelley, James Hoover, Felix Gaehtgens, Abhyuday Data, 19 July 2022

Gartner Disclaimers
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About CyberArk
CyberArk (NASDAQ: CYBR ) is the global leader in Identity Security. Centered on privileged access management , CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud workloads and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com , read the CyberArk blogs or follow on Twitter via @CyberArk , LinkedIn or Facebook .

Copyright © 2022 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release

Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early

Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse

Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 12:30:00 CEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 12:00:00 CEST | Press release

Aker BP joins as the first customer to scale agent-to-agent operations through a new generation of industrial agentic workflow applications Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting

BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 12:00:00 CEST | Press release

Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipeline BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data undersco

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye